Skip to content

Search

Showing results for "mental health aboriginal"

Study finds high RSV awareness with parents open to future immunisation

A The Kids Research Institute Australia study designed to gauge community awareness of respiratory syncytial virus (RSV) has found parents and parents-to-be are highly aware of the virus and are open to immunisation to tackle it.

Whooping cough studies

How protective is the whooping cough vaccine? Vaccination and allergy Even though Australia has high vaccination rates against whooping cough, we

2018 Round 1 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful applications for the 2018 Round 1 Wesfarmers Centre Seed Funding. The Wesfarmers Centre

COVID-19 Update: 27 June 2021

COVID-19 27 June 2021 Update: It is business as usual for ORIGINS, though masks must be worn.

World-first research helps to identify child developmental delays

The ORIGINS Project’s Early Moves study is investigating whether a baby’s early movements can predict learning difficulties later in childhood.

WA Kids Cancer Centre

The WA Kids Cancer Centre brings together clinicians and researchers working together to defeat childhood cancer.

WA Kids Cancer Centre researchers appointed to Brain Cancer Expert Advisory Panel

Dr Jessica Buck and Associate Professor Raelene Endersby have been appointed to the prestigious Australian Brain Cancer Mission Expert Advisory Panel.

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL.

Malignant Melanoma in Children and Adolescents Treated in Pediatric Oncology Centers: An Australian and New Zealand Children’s Oncology Group (ANZCHOG) Study

Unlike adults, malignant melanoma in children and adolescents is rare. In adult melanoma, significant progress in understanding tumor biology and new treatments, including targeted therapies and immunotherapy have markedly improved overall survival. In sharp contrast, there is a paucity of data on the biology and clinical behavior of pediatric melanoma. We report a national case series of all pediatric and adolescent malignant melanoma presenting to ANZCHOG Childhood Cancer Centers in Australia and New Zealand.

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL.